Hologic Inc. (Nasdaq: HOLX) announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Panther Fusion® SARS-CoV-2/Flu A/B/RSV assay. This assay is a molecular diagnostic test that detects and differentiates four of the most prevalent respiratory viruses that can exhibit similar clinical symptoms: severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza A (flu A), influenza B (flu B) and respiratory syncytial virus (RSV).

The first diagnostic test for long COVID is now available to patients across Australia. The test can help physicians diagnose long COVID by differentiating it from other diseases with similar symptoms, and to design personalized treatment approaches.

LumiraDx on Tuesday reported an 82 percent year-over-year decrease in first quarter revenues due to falling demand for COVID-19 testing.

DiaSorin said that its first quarter 2023 revenues fell 19 percent year over year on a sharp decline in COVID-19 testing, partially offset by growth in its non-COVID-19-related diagnostics revenues.

From March 15, China has officially announced the resumption of all kinds of visas, including tourist visas (L Visa), and visa-free policies have been reinstated.

The World Health Organization on Friday announced that COVID-19 is no longer a global emergency, marking a symbolic end to the pandemic, which has taken 7 million lives around the world. The move is deemed a natural one given the current stable situation.

Lucira Health, which broke new ground in 2020 with the first rapid at-home COVID-19 test but filed for bankruptcy this year, said in a recent US Securities and Exchange Commission filing that it has been acquired by Pfizer for $36.4 million through a bankruptcy auction.

Labcorp, a leading global life sciences company, today announced results for the first quarter ended March 31, 2023, and updated full-year guidance.

Qiagen said Monday that its QIAstat-Dx syndromic testing system is expected to be available soon in Japan with a SARS-CoV-2 Respiratory Panel that can detect more than 20 pathogens from a patient sample.

China's foreign ministry said on Tuesday that all inbound travellers will only need to show COVID-19 antigen tests result taken within 48 hours before boarding flights starting April 29, dropping the PCR test requirement.